InsiderTrades

Form 4 for TNXP Tonix Pharmaceuticals Holding Corp.

Accepted 2025-02-27 00:00:00 ET · period of report 2025-02-05 · accession 0001839882-25-011952 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2025-02-27 2025-02-05 TNXP LEDERMAN SETH CEO, Dir J - Other $0.718 -1.22 1 -55% -$0.88
D 2025-02-27 2025-02-05 TNXP LEDERMAN SETH CEO, Dir J - Other $3.38 -5.18 5 -51% -$17.51
DM 2025-02-27 2025-02-25 TNXP LEDERMAN SETH CEO, Dir A - Grant $0.00 +247.9K 124.0K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock, $0.001 par value 2025-02-05 J D 1 $0.15 0 I — —
2 Common Common Stock, $0.001 par value 2025-02-05 J D 5.18 $3.38 5 D By IRA Account — —
3 Common Common Stock, $0.001 par value 2025-02-05 J D 0.22 $3.30 1 I By Spouse — —
4 Derivative Stock Option 2025-02-25 A A 123,958 $0.00 123,958 D $10.06 · 2026-02-25 to 2035-02-25 123,958 Common Stock (F4) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. (F3) One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
5 Derivative Stock Option 2025-02-25 A A 123,958 $0.00 123,958 D $8.05 · 2026-02-25 to 2035-02-25 123,958 Common Stock (F4) The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. (F3) One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.